TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25827430

Group type: EXPERIMENTAL
Intervention: 7-day low-sodium diet (51.3 mmol sodium/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 7-day high-sodium diet (307.8 mmol sodium/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 7-day high-sodium diet with potassium supplementation (307.8 mmol sodium/day and 60 mmol potassium/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline log-transformed UAGT and UAGT/Cr ratio
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-sodium intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-sodium to high-sodium intervention
Number of subjects: 100
Study: 23359520

Group type: EXPERIMENTAL
Intervention: Pycnogenol® 150 mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 20798386

Group type: EXPERIMENTAL
Intervention: High-dose isoflavones (20 g of soy protein containing 160 mg of total isoflavones)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (20 g whole milk protein)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-dose isoflavones
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 18781287

Group type: EXPERIMENTAL
Intervention: Topical azithromycin ophthalmic solution 1% plus warm compresses
Number of subjects: 21

Group type: COMPARATOR
Intervention: Warm compresses alone
Number of subjects: 21
Study: 16569248

Group type: EXPERIMENTAL
Intervention: Early administration of atropine during dobutamine stress echocardiogram (group C at 40 mcg/kg/min of dobutamine)
Number of subjects: 121
Study: 14599854

Group type: EXPERIMENTAL
Intervention: Intravenous daclizumab infusions (anti-IL-2 receptor alpha)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Subcutaneous daclizumab formulation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous daclizumab infusions (6-week intervals)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous daclizumab infusions (2- to 4-week intervals)
Number of subjects: 15
Study: 10952473

Group type: COMPARATOR
Intervention: Buflomedil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naftidrofuryl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 0
Study: 9197448

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 5 microg/24 h
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 10 microg/24 h
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 5 microg/24 h and 10 microg/24 h
Number of subjects: 112
Study: 7570621

Group type: EXPERIMENTAL
Intervention: Inhalation exposure to toluene diisocyanate (TDI) vapors
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unexposed individuals
Number of subjects: 10
Study: 3739806

Group type: EXPERIMENTAL
Intervention: Tobacco
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-smoking sessions)
Number of subjects: 0
Study: 31657625

Group type: EXPERIMENTAL
Intervention: Telehomecare (THC) system for 3 months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 92
Study: 30021554

Group type: EXPERIMENTAL
Intervention: supervised exercise
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: facility access
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: self‐monitoring
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: group‐based active living counseling
Number of subjects: 500
Study: 27702719

Group type: EXPERIMENTAL
Intervention: Cod skin peptide (CSPE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24884807

Group type: EXPERIMENTAL
Intervention: Chest Pain Choice (CPC) decision aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22958541

Group type: EXPERIMENTAL
Intervention: Nurse-led support
Number of subjects: 418

Group type: COMPARATOR
Intervention: Lay-trainer support
Number of subjects: 418
Study: 20419336

Group type: EXPERIMENTAL
Intervention: PICI% <or= 74%
Number of subjects: 190
Study: 18362100

Group type: EXPERIMENTAL
Intervention: Cod liver oil (10 g containing 2.2 g of n-3 EFAs)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (air-filled identical capsules)
Number of subjects: 97
Study: 17114971

Group type: EXPERIMENTAL
Intervention: Biphasic shock
Number of subjects: 120

Group type: COMPARATOR
Intervention: Monophasic shock
Number of subjects: 120
Study: 14626187

Group type: EXPERIMENTAL
Intervention: Auricular acupoint pressing (AAP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study: 10612774

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (on pump) with intermittent antegrade warm blood cardioplegia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgery on the beating heart (off pump)
Number of subjects: 60
Study: 9193837

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 1358003

Group type: EXPERIMENTAL
Intervention: High-dose esmolol (300 micrograms.kg‐1.min‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Medium-dose esmolol (200 micrograms.kg‐1.min‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose esmolol (100 micrograms.kg‐1.min‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study: 2997306

Group type: EXPERIMENTAL
Intervention: Pentopril (CGS 13945) 125 mg capsules administered in the fasting state
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentopril (CGS 13945) 125 mg capsules administered after ingestion of a standardized meal
Number of subjects: 8
Study: 30887250

Group type: EXPERIMENTAL
Intervention: PF-06650808 at dose levels ≤2.0 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PF-06650808
Number of subjects: 40
Study: 31119173

Group type: EXPERIMENTAL
Intervention: VR combined with exercise imagery (running group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: VR distraction (driving group)
Number of subjects: 52
Study: 30236568

Group type: EXPERIMENTAL
Intervention: Warm intravenous fluids (Ringer's solution at 38°C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room temperature intravenous fluids (Ringer's solution)
Number of subjects: 0
Study: 26934850

Group type: EXPERIMENTAL
Intervention: Icodextrin instillation in the abdominal cavity
Number of subjects: 283

Group type: COMPARATOR
Intervention: Standard surgery without icodextrin
Number of subjects: 283
Study: 25008546

Group type: EXPERIMENTAL
Intervention: Tozadenant 120 mg twice daily
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Tozadenant 180 mg twice daily
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 22067661

Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% patch)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Low-dose capsaicin (0.04% control patch)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: NGX-4010 (30-minute application)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Low-dose capsaicin (30-minute control)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: NGX-4010 (60-minute application)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Low-dose capsaicin (60-minute control)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Total NGX-4010 group
Number of subjects: 494
Study: 19400487

Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 0.15% 4.5 mg (3 ml)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 0.15% 6.0 mg (4 ml)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 0.15% 7.5 mg (5 ml)
Number of subjects: 150
Study: 17225043

Group type: EXPERIMENTAL
Intervention: Vocational-oriented intervention (education, reassurance, motivation, vocational counselling)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Vocational-oriented intervention
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (life satisfaction, disability, fear avoidance behaviour, expectancy)
Number of subjects: 89
Study: 14722542

Group type: EXPERIMENTAL
Intervention: Hyoscine N-butyl bromide (40 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 120
Study: 11533544

Group type: EXPERIMENTAL
Intervention: Hydroxyethylamide 6% (MW 200 kDa SD 0.5)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Modified fluid gelatine (MFG) 4% (MW 30 kDa)
Number of subjects: 126
Study: 9609575

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 63
Study: 8193885

Group type: EXPERIMENTAL
Intervention: FSE sequence (TR = 4000 ms, effective TE = 100 ms, 2 NEX)
Number of subjects: 35

Group type: COMPARATOR
Intervention: T2‐weighted SE sequence (TR = 2000 ms, TE = 90 ms, 1‐2 NEX)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: FSE sequence
Number of subjects: 35
Study: 3400079

Group type: EXPERIMENTAL
Intervention: Acitretin (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Etretinate (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30821829

Group type: EXPERIMENTAL
Intervention: Statin therapy for 5 years (HPS trial)
Number of subjects: 45029

Group type: EXPERIMENTAL
Intervention: Incident stroke
Number of subjects: 45029

Group type: EXPERIMENTAL
Intervention: Incident transient ischemic attack, myocardial infarction, heart failure, and new-onset diabetes
Number of subjects: 45029
Study: 27262301

Group type: EXPERIMENTAL
Intervention: FEC-chemotherapy
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: ECOG 0
Number of subjects: 1322
Study: 26701648

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (rt-PA)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no rt-PA)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Pre-randomization arterial obstruction attenuation
Number of subjects: 109
Study: 23132904

Group type: EXPERIMENTAL
Intervention: Community-based exercise intervention for 10 weeks
Number of subjects: 121
Study: 21838092

Group type: EXPERIMENTAL
Intervention: Bilateral complete nasal packing without airway (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nasal packing with airway on one side (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nasal packing with airway on both sides (Group C)
Number of subjects: 90
Study: 19786682

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 264
Study: 16857111

Group type: EXPERIMENTAL
Intervention: Endoscopic endoprosthesis insertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-expandable metallic prostheses
Number of subjects: 0
Study: 15136391

Group type: EXPERIMENTAL
Intervention: Standardized acupuncture treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mock transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 36
Study: 11532742

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (150 microg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9247389

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8319490

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% ophthalmic suspension
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (LE vehicle)
Number of subjects: 113
Study: 3546274

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 34
Study: 31615861

Group type: EXPERIMENTAL
Intervention: Community members
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Responders
Number of subjects: 1648
Study: 28178145

Group type: EXPERIMENTAL
Intervention: Low-frequency high-intensity interval training (LfHIIT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 33
Study: 25966339

Group type: EXPERIMENTAL
Intervention: cART initiated one week after TB therapy
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: cART initiated four weeks after TB therapy
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: cART initiated eight weeks after TB therapy
Number of subjects: 478
Study: 23089653

Group type: EXPERIMENTAL
Intervention: Intraoral mucoadhesive tablet of amitriptyline
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 22358273

Group type: EXPERIMENTAL
Intervention: BiPAP® group (BG) with conventional respiratory therapy and BiPAP® for 30 minutes twice a day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control Group (CG) with conventional respiratory therapy only
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (CG and BG)
Number of subjects: 26
Study: 19231641

Group type: EXPERIMENTAL
Intervention: 1.0% lidocaine with 1:100,000 epinephrine
Number of subjects: 149

Group type: COMPARATOR
Intervention: 0.5% lidocaine with 1:200,000 epinephrine
Number of subjects: 149
Study: 16490021

Group type: EXPERIMENTAL
Intervention: Sex therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gingko biloba
Number of subjects: 24
Study: 12708976

Group type: EXPERIMENTAL
Intervention: DB PCFC with metabisulfite‐free seasoning (up to 1340 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prick tests with allergenic extract
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prick tests with B. nigra ground seeds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prick tests with B. juncea flour
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prick tests with metabisulfite‐free mustard seasoning
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Specific IgE values in mustard allergy subgroup
Number of subjects: 30
Study: 10743796

Group type: EXPERIMENTAL
Intervention: TNFbp dimer (30 microg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TNFbp dimer (100 microg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TNFbp dimer (300 microg/kg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 8811328

Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (sugar pie)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High lipid meal (whipped cream)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein meal (beef steak or fish fillet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein meal (beef or fish)
Number of subjects: 0
Study: 1547673

Group type: EXPERIMENTAL
Intervention: Long-acting zinc insulin (Ultratard HM) before the evening meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intermediate isophane insulin (Protaphane HM) before the evening meal
Number of subjects: 10
Study: 3908643

Group type: EXPERIMENTAL
Intervention: Interproximal root planing augmented by papilla reflection and fiber optic illumination (Group I)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Interproximal root planing with papilla reflection only (Group II)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Untreated controls (Group III)
Number of subjects: 4
Study: 30587728

Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 40 mg daily
Number of subjects: 69

Group type: COMPARATOR
Intervention: Anastrozole (ANA) 1 mg daily
Number of subjects: 69
Study: 26905871

Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA‐MRI
Number of subjects: 354

Group type: COMPARATOR
Intervention: ECCM‐MRI
Number of subjects: 354

Group type: COMPARATOR
Intervention: CE‐MDCT
Number of subjects: 354
Study: 25243534

Group type: COMPARATOR
Intervention: +CS
Number of subjects: 197

Group type: COMPARATOR
Intervention: -CS
Number of subjects: 197
Study: 22311837

Group type: EXPERIMENTAL
Intervention: Pretraining session with low-fidelity training models
Number of subjects: 14

Group type: COMPARATOR
Intervention: No pretraining
Number of subjects: 14
Study: 20487119

Group type: EXPERIMENTAL
Intervention: ICE plus fluoroscopy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fluoroscopy alone
Number of subjects: 43
Study: 17485593

Group type: EXPERIMENTAL
Intervention: Very late stent thrombosis patients
Number of subjects: 157
Study: 16207824

Group type: EXPERIMENTAL
Intervention: HbA(1c) measured at baseline
Number of subjects: 840
Study: 11886769

Group type: EXPERIMENTAL
Intervention: 7-day transdermal sequential estradiol/levonorgestrel patch (Fem7 Combi; 50 microg estradiol/10 microg levonorgestrel per 24 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study: 12516795

Group type: EXPERIMENTAL
Intervention: Head movement during pointing task
Number of subjects: 26

Group type: COMPARATOR
Intervention: No head movement during pointing task
Number of subjects: 26
Study: 9572224

Group type: EXPERIMENTAL
Intervention: Ultrasound screening during pregnancy
Number of subjects: 3265

Group type: COMPARATOR
Intervention: Nonscreening (control) group
Number of subjects: 3265

Group type: EXPERIMENTAL
Intervention: Ultrasound-exposed children
Number of subjects: 3265

Group type: COMPARATOR
Intervention: Ultrasound-unexposed children (control)
Number of subjects: 3265
Study: 7999858

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a dosage of 28-30 IU/m2/week for at least 12 months
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 31
Study: 3045717

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for three days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Trimethoprim 300 mg once daily for three days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 100
Study: 31129907

Group type: EXPERIMENTAL
Intervention: CEA-intensive regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT-intensive regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined CEA+CT regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimum surveillance regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 0
Study: 27843040

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg by mouth daily starting postoperative day 1 for 15 days
Number of subjects: 3914
Study: 26476515

Group type: EXPERIMENTAL
Intervention: Pack free septoplasty
Number of subjects: 49
Study: 23448618

Group type: EXPERIMENTAL
Intervention: Solvent/detergent plasma (S/D Plasma)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 63
Study: 21203797

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 18458326

Group type: EXPERIMENTAL
Intervention: Coadministration of recombinant human leptin and the amylin analog pramlintide
Number of subjects: 0
Study: 16799034

Group type: EXPERIMENTAL
Intervention: timolol 0.5%
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: brimonidine 0.2%
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: dorzolamide 2%
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 27
Study: 12686331

Group type: EXPERIMENTAL
Intervention: Isolated troponin elevation (without CK-MB elevation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isolated CK-MB elevation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both troponin and CK-MB positive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both markers negative
Number of subjects: 0
Study: 10807440

Group type: EXPERIMENTAL
Intervention: Continuous atrial dynamic overdrive pacing for 24 hours
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no atrial pacing)
Number of subjects: 96
Study: 8826488

Group type: EXPERIMENTAL
Intervention: 5% lidocaine patches applied for 12 hours in two of four sessions
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 5% lidocaine patches
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vehicle patches applied for 12 hours in one session
Number of subjects: 35

Group type: COMPARATOR
Intervention: No-treatment observation session
Number of subjects: 35
Study: 1425656

Group type: EXPERIMENTAL
Intervention: 20-MST
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous running track test (T1)
Number of subjects: 12
Study: 31174576

Group type: EXPERIMENTAL
Intervention: Eliglustat
Number of subjects: 393
Study: 30382274

Group type: EXPERIMENTAL
Intervention: Daily dose of 8 g of dried grape pomace
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 27178738

Group type: EXPERIMENTAL
Intervention: Gabapentin 600mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 25006110

Group type: EXPERIMENTAL
Intervention: Structured session/handout specific to their primary care provider (PCP)
Number of subjects: 332
Study: 22525652

Group type: EXPERIMENTAL
Intervention: Creatine ingestion (0.3 g/kg/die for 5 consecutive days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20950385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 17699010

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 10613
Study: 16275530

Group type: EXPERIMENTAL
Intervention: Low-power contrast echocardiography (CE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unenhanced harmonic echocardiography (HE)
Number of subjects: 36
Study: 12377150

Group type: EXPERIMENTAL
Intervention: Caffeine consumption in high users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine consumption in low users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine consumption
Number of subjects: 0
Study: 9927124

Group type: EXPERIMENTAL
Intervention: Laparoscopic or open Nissen fundoplication (in 1 case Toupet 180 degrees posterior hemifundoplication)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 7677387

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.1 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rilmenidine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2196934

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg orally at the time of IUCD insertion
Number of subjects: 1813